Delving into the Latest Updates on Paclitaxel/Cisplatin with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

TP

Target

DNA x Tubulin

Mechanism

DNA inhibitors(DNA inhibitors), Tubulin inhibitors, DNA alkylating agents

+ [2]

Therapeutic Areas

Neoplasms

Active Indication

Locally Advanced Head and Neck Squamous Cell Carcinoma

Inactive Indication-

Originator Organization

Tianjin Cancer Institute

Active Organization

Tianjin Cancer Institute

Inactive Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

Structure

Molecular FormulaC47H51NO14

InChIKeyRCINICONZNJXQF-MZXODVADSA-N

CAS Registry33069-62-4

View All Structures (2)

This is a single-center, single-arm, phase II study, aiming to preliminarily explore the efficacy and safety of JS004 combined with toripalimab and chemotherapy for perioperative treatment of locally advanced thoracic esophageal squamous cell carcinoma that is resectable. The plan is to enroll 20 patients with locally advanced resectable thoracic esophageal cancer. In the neoadjuvant treatment phase, patients will receive JS004 + toripalimab + chemotherapy (paclitaxel + cisplatin) for 2 cycles. This will be followed by the surgical phase: surgery will be performed 3-8 weeks after the last dose of neoadjuvant treatment. In the postoperative maintenance treatment phase, maintenance treatment will start 4 weeks ± 7 days after surgery, but no later than 10 weeks after surgery. For patients with R0 resection confirmed by postoperative pathology, they will receive maintenance treatment with JS004 + toripalimab for up to 15 cycles. For patients with non-R0 resection, they will receive maintenance treatment with JS004 + toripalimab combined with standard radiation or chemotherapy (selected by the investigator based on esophageal cancer guidelines). During the study, the maximum number of cycles of JS004 combined with toripalimab is 17 cycles (approximately 1 year).

Start Date30 Sep 2024

Sponsor / Collaborator

Henan Provincial Peoples Hospital

NCT06444009 / Not yet recruitingPhase 2IIT

Neoadjuvant Immunotherapy in Combination With Chemotherapy in Resectable Head and Neck Cancer：A Randomized, Phase II Study

A Randomized, Phase II Study of ivonescimab or cadonilimab or penpulimab in Combination With Cisplatin and Nab-paclitaxel in Patients With III-IVB (according to the 8th edition of UICC/AJCC staging) locally advanced head and neck squamous cell carcinoma (HNSCC) eligible for resection. This proposed study will evaluate the efficacy and safety of preoperative administration of ivonescimab or cadonilimab or penpulimab combined with chemotherapy in HNSCC who are eligible for resection.

Start Date01 Jun 2024

Sponsor / Collaborator

West China Hospital

NCT05520619 / Active, not recruitingPhase 2IIT

Tislelizumab Plus Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Patients with Locally Advanced Esophageal Squamous Cell Carcinoma: a Phase II, Randomized Trial (EC-CRT-002)

Definitive chemoradiotherapy (CRT) is the standard treatment option for unresectable locally advanced esophageal cancer (EC). However, as high as more than 40% of EC patients experienced locoregional recurrence after concurrent CRT. Immunotherapy targeting the PD-1/PD-L1 checkpoints has demonstrated promising activity in advanced EC. Recently, the combination of immunotherapy with CRT has emerged as a promising strategy to improve clinical outcomes in EC. The aim of this study was to evaluate whether the efficacy of tislelizumab (an anti-PD-1 antibody) plus induction chemotherapy followed by concurrent chemoradiotherapy would achieve a ≥71% 1-year progression-free survival rate, surpassing the historical 56% rate (NCT02403531) in patients with locally advanced esophageal squamous cell carcinoma (ESCC).

Start Date15 Sep 2022

Sponsor / Collaborator

Sun Yat-Sen University

[+2]

100 Clinical Results associated with Paclitaxel/Cisplatin

Login to view more data

100 Translational Medicine associated with Paclitaxel/Cisplatin

Login to view more data

100 Patents (Medical) associated with Paclitaxel/Cisplatin

Login to view more data

3,279

Literatures (Medical) associated with Paclitaxel/Cisplatin

31 Dec 2024·Scandinavian Cardiovascular Journal

Molecular mechanism of triptolide in myocardial fibrosis through the Wnt/β-catenin signaling pathway

Article

Author: Lu, Feng ; Zhang, Yiwen

Objective. Myocardial fibrosis (MF) is a common manifestation of end-stage cardiovascular diseases. Triptolide (TP) provides protection against cardiovascular diseases. This study was to explore the functional mechanism of TP in MF rats via the Wnt/β-catenin pathway. Methods. The MF rat model was established via subcutaneous injection of isoproterenol (ISO) and treated with low/medium/high doses of TP (L-TP/M-TP/H-TP) or Wnt agonist BML-284. Cardiac function was examined by echocardiography. Pathological changes of myocardial tissues were observed by HE and Masson staining. Col-I/Col-III/Vimentin/α-SMA levels were detected by immunohistochemistry, RT-qPCR, and Western blot. Collagen volume fraction content was measured. Expression levels of the Wnt/β-catenin pathway-related proteins (β-catenin/c-myc/Cyclin D1) were detected by Western blot. Rat cardiac fibroblasts were utilized for in vitro validation experiments. Results. MF rats had enlarged left ventricle, decreased systolic and diastolic function and cardiac dysfunction, elevated collagen fiber distribution, collagen volume fraction and hydroxyproline content. Levels of Col-I/Col-III/Vimentin/α-SMA, and protein levels of β-catenin/c-myc/Cyclin D1 were increased in MF rats. The Wnt/β-catenin pathway was activated in the myocardial tissues of MF rats. TP treatment alleviated impairments of cardiac function and myocardial tissuepathological injury, decreased collagen fibers, collagen volume fraction, Col-I, Col-III, α-SMA and Vimentin levels, HYP content, inhibited Wnt/β-catenin pathway, with H-TP showing the most significant effects. Wnt agonist BML-284 antagonized the inhibitive effect of TP on MF. TP inhibited the Wnt/β-catenin pathway to repress the proliferation and differentiation of mouse cardiac fibroblasts in vitro. Conclusions. TP was found to ameliorate ISO-induced MF in rats by inhibiting the Wnt/β-catenin pathway.

31 Dec 2024·Pharmaceutical Biology

Comparative efficacy and safety of Chinese medicine injections as an adjunctive therapy for cervical cancer in Chinese patients: a network meta-analysis

Review

Author: Zhang, Hongxing ; Wang, Qun ; Song, Haiyan ; Ma, Fei ; Wang, Zihong ; Zhang, Di ; Liu, Xianghong ; Xie, Hui ; Sun, Shiguang

CONTEXTChinese medicine injections (CMIs) are widely used as adjuvant therapy for cervical cancer in China. However, the effectiveness of different types of CMIs remains uncertain.OBJECTIVETo assess the effectiveness and safety of CMIs when used in conjunction with radiotherapy (RT) or concurrent chemoradiotherapy (CCRT), particularly in combination with cisplatin (DDP), docetaxel plus cisplatin (DP), and paclitaxel plus cisplatin (TP).MATERIALS AND METHODSRandomized controlled trials (RCTs) were searched in databases including CNKI, WanFang, VIP, SinoMed, PubMed, Cochrane Library, Embase, and Web of Science from inception to September 2023. We calculated the risk ratio with a 95% confidence interval and the surface under the cumulative ranking area curve (SUCRA) for the clinical efficacy rate (CER), the efficacy rate by Karnofsky Performance Status (KPS), and the rates of leukopenia reduction (LRR) and gastrointestinal reactions (GRR).RESULTSForty-seven RCTs were included, including nine CMI types: Aidi, Fufangkushen, Huangqi, Kangai (KA), Kanglaite (KLT), Renshenduotang, Shenqifuzheng (SQFZ), Shenmai (SM), and Yadanzi. KLT and KA were likely optimal choices with radiotherapy for CER and KPS, respectively. KA and KLT were optimal choices with RT + DDP for CER and GRR, respectively. KLT was the likely optimal choice with RT + DP for CER and KA for both KPS and GRR. SM and SQFZ were the likely optimal choices with RT + TP for CER and LRR, respectively.CONCLUSIONSThe optimal recommendation depends on whether CMIs are used with radiotherapy or concurrent chemoradiotherapy. More high-quality RCTs are needed to confirm further and update the existing evidence.

01 Oct 2024·European Urology Oncology

Transperineal Versus Transrectal Magnetic Resonance Imaging–targeted Biopsies for Prostate Cancer Diagnosis: Final Results of the Randomized PERFECT trial (CCAFU-PR1)

Article

Author: Ploussard, Guillaume ; Barret, Eric ; Aziza, Richard ; Beauval, Jean-Baptiste ; Giannarini, Gianluca ; Rouprêt, Morgan ; Salin, Ambroise ; Malavaud, Bernard ; Descotes, Jean-Luc ; Rozet, François ; Lenfant, Louis ; Fiard, Gaëlle ; Renard-Penna, Raphaële ; Almeras, Christophe

BACKGROUNDRecent guidelines favor transperineal (TP) prostate biopsies over the transrectal (TR) approach due to a reduced sepsis risk. Yet, evidence from controlled trial comparing both approaches within the MRI-targeted pathway for significant prostate cancer (PCa) detection is lacking.OBJECTIVETo compare the significant PCa detection rate between magnetic resonance imaging (MRI)-targeted TR and TP approaches in biopsy-naïve patients.DESIGN, SETTING, AND PARTICIPANTSIn this noninferiority controlled trial, we randomized (ratio 1:1) 270 MRI-positive biopsy-naïve patients.INTERVENTIONMRI-targeted TP versus TR biopsy.OUTCOME MEASUREMENTS AND STATISTICAL ANALYSESThe primary outcome was the detection rate of significant PCa (International Society of Urological Pathology [ISUP] ≥2) in MRI-targeted biopsies. Secondary outcomes were any-grade PCa detection, detection on concomitant systematic biopsy, complications, and functional outcomes.RESULTS AND LIMITATIONSTargeted biopsies identified significant PCa in 47.2% of TP and 54.2% of TR participants (-7%, p = 0.6235). On a per-lesion analysis, posterior lesions yielded higher detection rates via TR (59.0% vs 44.3%, p = 0.0443), while anterior lesions were more frequently detected via TP (40.6% vs 26.5%, p = 0.2228). The overall (any grade) cancer detection rate in targeted biopsies was comparable between groups: 71.3% (TP) versus 64.1% (TR; p = 0.2209) with significantly more ISUP 1 cases detected in the TP arm. Adverse events of grade ≥2 were not different between TP (35.7%) and TR (40.5%, p = 0.4256). One TR patient (0.8%) experienced grade 3 sepsis. Quality of life, and urinary and sexual function, as well as pain scores, were comparable between groups.CONCLUSIONSDespite a comparable overall detection rate for any-grade PCa, noninferiority of TP over TR for MRI-targeted biopsies for significant PCa detection was not demonstrated. However, MRI lesion location influenced biopsy route performance, suggesting that a pragmatic approach based on lesion location might enhance significant PCa assessment.PATIENT SUMMARYThis trial compared the efficacy and safety of two biopsy approaches for prostate cancer diagnosis. Both approaches seem complementary according to the lesion location.

100 Deals associated with Paclitaxel/Cisplatin

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Locally Advanced Head and Neck Squamous Cell Carcinoma	Phase 2	CN	Tianjin Cancer Institute	07 Nov 2021

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ESMO_ASIA2023	Not Applicable	Locally Advanced Head and Neck Squamous Cell Carcinoma Neoadjuvant	21	Pembrolizumab plus TP	(njwuyqlcra) = nmxalcfsyt prcbjcwgix (udecqjeppv ) View more	-	02 Dec 2023
ESMO_ASIA2023	Not Applicable		21	Pembrolizumab plus DP	(njwuyqlcra) = hvdabvrasv prcbjcwgix (udecqjeppv ) View more	-	02 Dec 2023
ASCO2016	Phase 2	Recurrent Cervical Cancer	65	Cisplatin-Paclitaxel regimen	(ugrucojiox) = rqsmvgpytg bphbtikqua (jeudhjboek ) View more	Positive	20 May 2016
ASCO2015	Not Applicable	Locally Advanced Head and Neck Squamous Cell Carcinoma	-	Paclitaxel 80 mg/m2 plus cisplatin 75 mg/m2	(ipeltblafl) = uwidhflgut ewnpmnzato (xuuxvokrqj ) View more	-	20 May 2015
RTOG 0436 \| CA21661 & CCOP CA3742 NCI grants and Bristol Myers Squibb (ESMO_GI2014)	Phase 3	Esophageal Carcinoma	344	Cisplatin, Paclitaxel and Radiation with Cetuximab	(dttnbdawuq) = kxcykoeihj vddayhwuyl (gsbcortyhm, 36% - 52%) View more	Negative	25 Jun 2014
	Phase 3	Esophageal Carcinoma	344	Cisplatin, Paclitaxel and Radiation without Cetuximab	(dttnbdawuq) = ldorxtdehr vddayhwuyl (gsbcortyhm, 34% - 50%) View more	Negative	25 Jun 2014
ASCO2014	Not Applicable	Squamous Cell Carcinoma of the Penis	41	Paclitaxel plus cisplatin	(jswuiecwse) = kfdcxjyofd zllrfbpvhy (hxbhbuzbxu ) View more	-	20 May 2014
ASCO_GU2014	Not Applicable	Squamous Cell Carcinoma of the Penis Adjuvant \| Neoadjuvant	47	Paclitaxel plus cisplatin and 5-fluorouracil (T-PF)	(larzncrfed) = jjaoeldvqi lhrsahydrs (wyliwzynmd )	-	01 Feb 2014
WCLC2013	Not Applicable	Advanced Lung Squamous Cell Carcinoma	32	Docetaxel/cisplatin chemotherapy and thoracic radiotherapy	(towuyaokoe) = cbomlbwjwe dypjmicuay (jgsosbbyzz, 63 - 97) View more	-	29 Oct 2013
ASCO2013	Not Applicable	Locally Advanced Cervical Carcinoma	47	Cisplatin, paclitaxel, and capecitabine	odceynwumo(qpbdowswkj) = gktzuzmpno tstbwpmyvq (jcewmnxhjj ) View more	-	20 May 2013
ASCO2013	Not Applicable	Advanced Esophageal Squamous Cell Carcinoma	133	Paclitaxel plus cisplatin	(ymvgfxwybd) = fywdlvwffk myaizwfqmo (qdcwygildn, 5.68 - 8.32) View more	-	20 May 2013
ASCO2011	Phase 2	Non-Small Cell Lung Cancer	-	Paclitaxel plus cisplatin	(yqvykuatae) = bszelfhsby owsnijrdsh (ycxrymhuoo ) View more	Positive	20 May 2011
ASCO2011	Phase 2	Non-Small Cell Lung Cancer	-	Paclitaxel plus cisplatin with Cadi-05	(yqvykuatae) = xjuxjiogxc owsnijrdsh (ycxrymhuoo ) View more	Positive	20 May 2011